




For Physicians.  
For Patients.  
Reduces Mortality in ICD  
& CRT-D Patients with  
**Home Monitoring.**

**What is Home Monitoring?**


BIOTRONIK Home Monitoring™ (HM) is a method of remotely monitoring cardiac implantable electronic devices (CIEDs) from a transmitter in a patients home. BIOTRONIKs transmitter is called CardioMessenger Smart is the same size of a smart phone. It uses mobile technology to transmit data from the CIED to a secure server that only the patients clinical team can access (Cardiologist and Cardiac Physiologists, with the patients' consent).



**Daily Verification is unique to BIOTRONIK!**

BIOTRONIK are the only company that can transmit this data every day. This daily verification means that should the patient have symptoms, or the clinical team need to check the device, data is readily available and up to date.

Click on this link to listen to these UK Cardiac specialists on our BIOTRONIK YouTube channel ([click link](#)).



**Is there a complicated setup?**  
A simple click on your Renamic programmer activates the device.

Then register your patient on HMSC, hand a CardioMessenger to your patient and voila! No phone cables, no pairing, no dongles, no docking station, no buttons to push, no lights flashing.

**Simple, reliable & effective.**



For Physicians.  
For Patients.  
Reduces Mortality in ICD  
& CRT-D Patients with  
**Home Monitoring.**

**What's the evidence?**

BIOTRONIK have heavily supported clinical trials to evaluate the patient, clinical & economical advantages in three major trials, that were then pooled and analysed collectively in the TRUECOIN study, published in EHJ 2017 ([click link](#)). 2405 patients were monitored at 181 centers mainly in the USA, France and Germany.



**Key Clinical Results**

“Home Monitoring with daily transmission verification significantly reduced all-cause death and the composite endpoint of all-cause death or worsening heart failure (WHF) hospitalization. Similar magnitudes of absolute risk reductions for WHF and cardiovascular endpoints suggest that the benefit of Home Monitoring is driven by the prevention of heart failure exacerbation.”

Clinical Endpoint (at 12 Months)	Relative Risk Reduction	Absolute Risk Reduction	p < 0.05
All-cause death	38% ↓	1.9% ↓	p < 0.05
All-cause death or WHF hospitalization	36% ↓	5.6% ↓	p < 0.01

EARLY DETECTION  
FDA & CE approved\*

SAFE FOLLOW-UP REDUCTION  
FDA & CE approved\*

MORTALITY REDUCTION  
CE approved\* **NEW**

**Quick View - 31-Aug-2017**



Name: To: Ms Louise Lynch  
Patient ID: 87164246

Device status: On  
Battery status: 90%  
Battery voltage: 3.12 V (31-Aug-2017)  
Charging time: 1.9 h for 40.2 (28-Jun-2017 01:26:44)

Telemetry settings: Zone level: Off, Dual ATP: Off, Test shock: Off, Svc. rch. sh. ---  
VF: 200 bpm, Burst: 40.2, 40.2, 8 \* 40.2

Brady / CRT / AF settings: Mode: DDD / BiV / LV, Stim. rate / VTR (bpm): 70 / 140, Air delay: 120 ms, Mode switching: 140 bpm / DDDR

Brady mode: RA mode: RV mode: LV mode: ---  
Pacing impedance (ohm): ---, ---, ---, ---  
Pacing impedance SS: 0.8, 0.8, 0.8  
Sensing amp. / min / max (mV): + 8.0 / + 8.0, + 20.0 / + 20.0, + 20.0 / + 20.0  
Programmed (Dthru): 1.8 A / ICD @ 0.40, 1.8 A / ICD @ 0.40, 1.8 A / ICD @ 0.40

Vec. arrhythmias since 31-Mar-2017: VT1: 0, VT2: 0, VF: 0  
Therapy episodes: ATP delivered / Fails: 0 / 0, 0 / 0, 0 / 0  
 shocks delivered / Fails: 0 / 0, 0 / 0, 0 / 0  
 Laser episode: Pseudo: 154 (15-Aug-2017 01:44:34)

Atrial arrhythmias since 31-Mar-2017: Atrial burden: 17.3% of day  
Atrial arrhythmias during arr. burden: 12 bpm  
Atrial arrhythmias ongoing at end of main interv.: NO  
Atrial monitoring episodes: 31  
Number of mode switching per day: 4  
CRT episodes: 0

Event histogram from 01-Aug-2017 until 10-Aug-2017: AF: 22%, SVT: 27%, CRT: 97%

Lead trends: Pacing: ---, ---, ---, ---, ---  
Max. Ch. amp.: ---, ---, ---, ---, ---  
Pacing: ---, ---, ---, ---, ---  
Mode: ---, ---, ---, ---, ---

Using term trends: Pacing: ---, ---, ---, ---, ---  
Max. Ch. amp.: ---, ---, ---, ---, ---  
Pacing: ---, ---, ---, ---, ---  
Mode: ---, ---, ---, ---, ---

**Is it easy to use?** Take a quick view for yourself. All the information you need for a 360° look at your patients device function. **AND**, the only system on the market that can substantiate claims with FDA & CE approval.

Finally... check out other **HOT** clinical news presented at ESC last month?

**CASTLE-AF** results showed AF ablation reduced all cause mortality by 47%! Click here to learn more. Home Monitoring™ technology also aided the investigators in monitoring AF burden.